Literature DB >> 29274878

Immunochemical analysis of the expression of SV2C in mouse, macaque and human brain.

Amy R Dunn1, Carlie A Hoffman1, Kristen A Stout1, Minagi Ozawa1, Rohan K Dhamsania1, Gary W Miller2.   

Abstract

The synaptic vesicle glycoprotein 2C (SV2C) is an undercharacterized protein with enriched expression in phylogenetically old brain regions. Its precise role within the brain is unclear, though various lines of evidence suggest that SV2C is involved in the function of synaptic vesicles through the regulation of vesicular trafficking, calcium-induced exocytosis, or synaptotagmin function. SV2C has been linked to multiple neurological disorders, including Parkinson's disease and psychiatric conditions. SV2C is expressed in various cell types-primarily dopaminergic, GABAergic, and cholinergic cells. In mice, it is most highly expressed in nuclei within the basal ganglia, though it is unknown if this pattern of expression is consistent across species. Here, we use a custom SV2C-specific antiserum to describe localization within the brain of mouse, nonhuman primate, and human, including cell-type localization. We found that the immunoreactivity with this antiserum is consistent with previously-published antibodies, and confirmed localization of SV2C in the basal ganglia of rodent, rhesus macaque, and human. We observed strongest expression of SV2C in the substantia nigra, ventral tegmental area, dorsal striatum, pallidum, and nucleus accumbens of each species. Further, we demonstrate colocalization between SV2C and markers of dopaminergic, GABAergic, and cholinergic neurons within these brain regions. SV2C has been increasingly linked to dopamine and basal ganglia function. These antisera will be an important resource moving forward in our understanding of the role of SV2C in vesicle dynamics and neurological disease.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Antiserum; Basal ganglia; SV2C

Mesh:

Substances:

Year:  2017        PMID: 29274878      PMCID: PMC6013333          DOI: 10.1016/j.brainres.2017.12.029

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  44 in total

1.  Quantitative comparison of glutamatergic and GABAergic synaptic vesicles unveils selectivity for few proteins including MAL2, a novel synaptic vesicle protein.

Authors:  Mads Grønborg; Nathan J Pavlos; Irene Brunk; John J E Chua; Agnieszka Münster-Wandowski; Dietmar Riedel; Gudrun Ahnert-Hilger; Henning Urlaub; Reinhard Jahn
Journal:  J Neurosci       Date:  2010-01-06       Impact factor: 6.167

2.  Expression and function of SNAP-25 as a universal SNARE component in GABAergic neurons.

Authors:  Lawrence C R Tafoya; Manuel Mameli; Teiko Miyashita; John F Guzowski; C Fernando Valenzuela; Michael C Wilson
Journal:  J Neurosci       Date:  2006-07-26       Impact factor: 6.167

3.  Improving the specificity of immunological detection in aged human brain tissue samples.

Authors:  Anyang Sun; Mei Liu; Guoying Bing
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2009-12-02

4.  SV2 acts via presynaptic calcium to regulate neurotransmitter release.

Authors:  Qun-Fang Wan; Zhen-Yu Zhou; Pratima Thakur; Alejandro Vila; David M Sherry; Roger Janz; Ruth Heidelberger
Journal:  Neuron       Date:  2010-06-24       Impact factor: 17.173

5.  SV2C is a synaptic vesicle protein with an unusually restricted localization: anatomy of a synaptic vesicle protein family.

Authors:  R Janz; T C Südhof
Journal:  Neuroscience       Date:  1999       Impact factor: 3.590

6.  Influence of genetic, biological and pharmacological factors on levodopa dose in Parkinson's disease.

Authors:  Vivian Altmann; Artur F Schumacher-Schuh; Mariana Rieck; Sidia M Callegari-Jacques; Carlos R M Rieder; Mara H Hutz
Journal:  Pharmacogenomics       Date:  2016-03-29       Impact factor: 2.533

7.  Down-regulation synaptic vesicle protein 2A in the anterior temporal neocortex of patients with intractable epilepsy.

Authors:  Guibo Feng; Fei Xiao; Yang Lu; Zuchun Huang; Jie Yuan; Zheng Xiao; Zhiqin Xi; Xuefeng Wang
Journal:  J Mol Neurosci       Date:  2009-11       Impact factor: 3.444

8.  Increased vesicular monoamine transporter enhances dopamine release and opposes Parkinson disease-related neurodegeneration in vivo.

Authors:  Kelly M Lohr; Alison I Bernstein; Kristen A Stout; Amy R Dunn; Carlos R Lazo; Shawn P Alter; Minzheng Wang; Yingjie Li; Xueliang Fan; Ellen J Hess; Hong Yi; Laura M Vecchio; David S Goldstein; Thomas S Guillot; Ali Salahpour; Gary W Miller
Journal:  Proc Natl Acad Sci U S A       Date:  2014-06-16       Impact factor: 11.205

9.  A new antigen retrieval technique for human brain tissue.

Authors:  Raúl Alelú-Paz; Ignacio Iturrieta-Zuazo; William Byne; Vahram Haroutunian; Mercedes García-Villanueva; Alberto Rábano; María García-Amado; Lucía Prensa; José Manuel Giménez-Amaya
Journal:  PLoS One       Date:  2008-10-13       Impact factor: 3.240

10.  SV2 renders primed synaptic vesicles competent for Ca2+ -induced exocytosis.

Authors:  Wen-Pin Chang; Thomas C Südhof
Journal:  J Neurosci       Date:  2009-01-28       Impact factor: 6.167

View more
  5 in total

1.  Changes in the Gene Expression Profiles of the Inferior Colliculus Following Unilateral Cochlear Ablation in Adult Rats.

Authors:  Hog Kwon Kil; Kyung Woon Kim; Da-Hye Lee; So Min Lee; Chang Ho Lee; So Young Kim
Journal:  Biochem Genet       Date:  2021-01-30       Impact factor: 1.890

2.  Expression profile of synaptic vesicle glycoprotein 2A, B, and C paralogues in temporal neocortex tissue from patients with temporal lobe epilepsy (TLE).

Authors:  Burcu A Pazarlar; Sanjay S Aripaka; Viktor Petukhov; Lars Pinborg; Konstantin Khodosevich; Jens D Mikkelsen
Journal:  Mol Brain       Date:  2022-05-16       Impact factor: 4.399

3.  Mutant Huntingtin Causes a Selective Decrease in the Expression of Synaptic Vesicle Protein 2C.

Authors:  Chaohua Peng; Gaochun Zhu; Xiangqian Liu; He Li
Journal:  Neurosci Bull       Date:  2018-04-30       Impact factor: 5.203

Review 4.  Promising drug targets and associated therapeutic interventions in Parkinson's disease.

Authors:  Sachchida Nand Rai; Payal Singh; Ritu Varshney; Vivek K Chaturvedi; Emanuel Vamanu; M P Singh; Brijesh Kumar Singh
Journal:  Neural Regen Res       Date:  2021-09       Impact factor: 5.135

5.  Neuron-recognizable characteristics of peptides recombined using a neuronal binding domain of botulinum neurotoxin.

Authors:  Hye Rin Kim; Younghun Jung; Jonghyeok Shin; Myungseo Park; Dae-Hyuk Kweon; Choongjin Ban
Journal:  Sci Rep       Date:  2022-03-23       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.